[go: up one dir, main page]

BR0114785A - Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença. - Google Patents

Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença.

Info

Publication number
BR0114785A
BR0114785A BR0114785-4A BR0114785A BR0114785A BR 0114785 A BR0114785 A BR 0114785A BR 0114785 A BR0114785 A BR 0114785A BR 0114785 A BR0114785 A BR 0114785A
Authority
BR
Brazil
Prior art keywords
vaccine composition
present
composition
methods
antigen
Prior art date
Application number
BR0114785-4A
Other languages
English (en)
Inventor
Nathalie Garcon
Catherine Marie Ghislai Gerard
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BR0114785A publication Critical patent/BR0114785A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"COMPOSIçãO ADJUVANTE, COMPOSIçãO DE VACINA, E, MéTODOS PARA DESVIAR A QUALIDADE DE UMA RESPOSTA IMUNOLóGICA CONTRA UM ANTìGENO, PARA A MANUFATURA DE UMA COMPOSIçãO DE VACINA, E PARA TRATAR UM INDIVìDUO SUSCETìVEL A OU SOFRENDO DE UMA DOENçA". A presente invenção refere-se a composições adjuvantes inéditas para uso em vacinas. Em particular, as composições adjuvantes da presente invenção compreendem uma combinação de um oligonucleotídeo imunoestimulador e um tocol. A presente invenção também proporciona vacinas compreendendo as composições adjuvantes da presente invenção e pelo menos um antígeno. Proporciona-se também métodos de manufatura das composições adjuvantes e vacinas da presente invenção e seu uso como medicamentos. Adicionalmente, a presente invenção proporciona métodos de tratar um indivíduo suscetível a, ou sofrendo de, uma doença, através de administração parenteral ou mucosal das vacinas da presente invenção.
BR0114785-4A 2000-10-18 2001-10-16 Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença. BR0114785A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0025577.8A GB0025577D0 (en) 2000-10-18 2000-10-18 Vaccine
PCT/EP2001/011985 WO2002032454A1 (en) 2000-10-18 2001-10-16 Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol

Publications (1)

Publication Number Publication Date
BR0114785A true BR0114785A (pt) 2003-12-23

Family

ID=9901557

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114785-4A BR0114785A (pt) 2000-10-18 2001-10-16 Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença.

Country Status (21)

Country Link
US (1) US20040047869A1 (pt)
EP (1) EP1326639B1 (pt)
JP (1) JP2004511529A (pt)
KR (1) KR20030044016A (pt)
CN (1) CN100346829C (pt)
AT (1) ATE383872T1 (pt)
AU (2) AU2168902A (pt)
BR (1) BR0114785A (pt)
CA (1) CA2425310A1 (pt)
CZ (1) CZ20031094A3 (pt)
DE (1) DE60132474T2 (pt)
ES (1) ES2299530T3 (pt)
GB (1) GB0025577D0 (pt)
HU (1) HUP0303720A3 (pt)
IL (1) IL155283A0 (pt)
MX (1) MXPA03003406A (pt)
NO (1) NO20031646L (pt)
NZ (1) NZ525321A (pt)
PL (1) PL365322A1 (pt)
WO (1) WO2002032454A1 (pt)
ZA (1) ZA200302887B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
NZ513935A (en) * 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
BR0210628A (pt) * 2001-06-29 2004-08-10 Becton Dickinson Co Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
WO2003015711A2 (en) * 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004007525A2 (en) * 2002-07-10 2004-01-22 Akzo Nobel N. V. Immunogenic composition comprising a fusion protein and a saponin adjuvant
BR0315810A (pt) * 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
EP1608403A2 (en) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
EP1663316A2 (en) * 2003-09-25 2006-06-07 Coley Pharmaceutical Group, Inc. Nucleic acid lipophilic conjugates
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
EP1741438A4 (en) * 2004-04-22 2009-08-26 Dainippon Sumitomo Pharma Co PHARMACEUTICAL PREPARATION CONTAINING SKELETAL COMPONENT OF BACTERIAL CELL WALL
JP2008506789A (ja) * 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
TW200700078A (en) * 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Novel use
KR100740237B1 (ko) * 2005-05-10 2007-07-18 아이진 주식회사 올리고뉴클레오타이드 및 비독성 다당체를 포함하는면역보조제
WO2007008463A2 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
WO2007052059A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Changing th1/th2 balance in split influenza vaccines with adjuvants
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
DE102006035618A1 (de) * 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
EP2046954A2 (en) 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
EP2484375B1 (en) * 2006-09-26 2018-05-23 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2008043774A1 (en) * 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
KR101483715B1 (ko) 2008-01-31 2015-01-19 큐어백 게엠바하 면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
EP3725328A3 (en) 2008-06-27 2020-12-23 Zoetis Services LLC Novel adjuvant compositions
WO2010017330A1 (en) * 2008-08-06 2010-02-11 Novartis Ag Microparticles for use in immunogenic compositions
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
DK2850431T3 (en) 2012-05-16 2018-07-16 Immune Design Corp Vaccines against HSV-2
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
CN105764525A (zh) 2013-09-19 2016-07-13 硕腾服务有限责任公司 油基佐剂
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
PL3244920T3 (pl) 2015-01-16 2023-09-25 Zoetis Services Llc Szczepionka przeciw pryszczycy
CN115025211A (zh) * 2021-11-02 2022-09-09 南京理工大学 用于动脉粥样硬化治疗的纳米疫苗及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2068989T3 (es) * 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物

Also Published As

Publication number Publication date
AU2168902A (en) 2002-04-29
EP1326639A1 (en) 2003-07-16
PL365322A1 (en) 2004-12-27
NO20031646L (no) 2003-06-14
IL155283A0 (en) 2003-11-23
HUP0303720A3 (en) 2004-11-29
ES2299530T3 (es) 2008-06-01
CZ20031094A3 (cs) 2003-09-17
KR20030044016A (ko) 2003-06-02
GB0025577D0 (en) 2000-12-06
EP1326639B1 (en) 2008-01-16
DE60132474T2 (de) 2009-01-15
AU2002221689B2 (en) 2004-04-01
NO20031646D0 (no) 2003-04-10
HUP0303720A2 (hu) 2004-03-29
DE60132474D1 (de) 2008-03-06
JP2004511529A (ja) 2004-04-15
WO2002032454A1 (en) 2002-04-25
US20040047869A1 (en) 2004-03-11
NZ525321A (en) 2004-06-25
ATE383872T1 (de) 2008-02-15
CN100346829C (zh) 2007-11-07
ZA200302887B (en) 2004-07-12
CN1481254A (zh) 2004-03-10
CA2425310A1 (en) 2002-04-25
MXPA03003406A (es) 2005-01-25

Similar Documents

Publication Publication Date Title
BR0114785A (pt) Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença.
PL351893A1 (en) Vaccines
CN103025351B (zh) 包含胆固醇和作为唯一的佐剂-载剂分子的cpg的疫苗
BR9507400A (pt) Composições imunogénicas de polissacaridio streptococal grupo a e processos
PH12023553205A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2001066123A3 (en) Composition consisting of phy906 and chemotherapeutic agents
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
NO20015074D0 (no) Nye sammensetninger
JP2003513935A5 (pt)
MX2024008039A (es) Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.
CA2646574A1 (en) Vaccine against mycoplasma and prrsv
TR200001948T2 (tr) Mikobakteri vaccaesinden türetilen kompozisyonlar ve bunların kullanımları için metotlar.
WO2002032378A3 (en) Fusion cells and cytokine compositions for treatment of disease
WO2002053176A3 (en) An autologous anti-cancer vaccine
MY127452A (en) Vaccines.
WO2001022994A3 (en) Vaccines against neisseria infection
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2025186705A8 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR9916771A (pt) Composição tlp imunogência
HK1177589B (en) Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.